TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39183448

Group type: EXPERIMENTAL
Intervention: CDC training module
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: TRAIN + CDC training module
Number of subjects: 103
Study: 39183572

Group type: EXPERIMENTAL
Intervention: Endovenous microwave ablation
Number of subjects: 50
Study: 39184059

Group type: EXPERIMENTAL
Intervention: Single-use cholangioscope for percutaneous transhepatic cholangioscopy
Number of subjects: 0
Study: 39184092

Group type: EXPERIMENTAL
Intervention: Ribociclib
Number of subjects: 14
Study: 39184097

Group type: EXPERIMENTAL
Intervention: Hybrid-delivery model (remote mHealth delivery via smartphones with audiovisual content and WhatsApp interactions)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: In-person group-based delivery model
Number of subjects: 1200
Study: 39184944

Group type: EXPERIMENTAL
Intervention: eLIFEwithIBD intervention (ACT and compassion-based online intervention) + medical TAU
Number of subjects: 55

Group type: COMPARATOR
Intervention: Medical TAU
Number of subjects: 55
Study: 39184998

Group type: EXPERIMENTAL
Intervention: AGuIX nanoparticles (4 injections at 50, 75, and 100 mg/kg) with radiotherapy (RT 60 Gy) and concomitant/adjuvant temozolomide (TMZ)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: AGuIX nanoparticles (100 mg/kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: AGuIX nanoparticles
Number of subjects: 8
Study: 39185280

Group type: EXPERIMENTAL
Intervention: Shock Advisory System (SAS) with Analyze Whilst Compressing (AWC) algorithm
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Shock Advisory System (SAS) with AWC algorithm
Number of subjects: 285

Group type: COMPARATOR
Intervention: Standard CPR
Number of subjects: 285
Study: 39185360

Group type: EXPERIMENTAL
Intervention: Transcranial static magnetic stimulation (tSMS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 40
Study: 39185368

Group type: EXPERIMENTAL
Intervention: Reduced noise environment during induction and emergence
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (standard noise environment)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Reduced noise environment
Number of subjects: 64
Study: 39185513

Group type: EXPERIMENTAL
Intervention: Baseline serum neurofilament light (NfL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum NfL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood NfL
Number of subjects: 0
Study: 39185526

Group type: EXPERIMENTAL
Intervention: ICECaP intervention (Individualized Coordination and Empowerment for Care Partners of Persons with Dementia)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Routine clinical support (control)
Number of subjects: 130
Study: 39185528

Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 0
Study: 39185538

Group type: EXPERIMENTAL
Intervention: MASLIHAT intervention
Number of subjects: 420

Group type: COMPARATOR
Intervention: Comparison health education training (TANSIHAT)
Number of subjects: 420
Study: 39185596

Group type: EXPERIMENTAL
Intervention: SLFN11-positive tumors (e.g., mesotheliomas, clear cell renal cell carcinomas, small cell lung cancers, squamous cell carcinomas of the tonsil and larynx, ovarian serous carcinomas)
Number of subjects: 6658

Group type: EXPERIMENTAL
Intervention: SLFN11-negative tumors (e.g., hepatocellular, prostatic, colorectal, breast cancers)
Number of subjects: 6658

Group type: EXPERIMENTAL
Intervention: Neuroectodermal and mesenchymal tumors
Number of subjects: 6658

Group type: EXPERIMENTAL
Intervention: Absence of SLFN11 expression
Number of subjects: 6658
Study: 39185955

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily plus Aspirin 100 mg once daily
Number of subjects: 88

Group type: COMPARATOR
Intervention: Aspirin 100 mg once daily
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 88
Study: 39186143

Group type: EXPERIMENTAL
Intervention: Add-on dupilumab therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Background therapy alone
Number of subjects: 0
Study: 39186271

Group type: EXPERIMENTAL
Intervention: Trastuzumab for 9 weeks
Number of subjects: 2174

Group type: COMPARATOR
Intervention: Trastuzumab for 1 year
Number of subjects: 2174
Study: 39186268

Group type: EXPERIMENTAL
Intervention: Modified directly observed therapy
Number of subjects: 415

Group type: COMPARATOR
Intervention: Patient navigation
Number of subjects: 415
Study: 39186273

Group type: EXPERIMENTAL
Intervention: Islamic Trauma Healing (ITH)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Waiting List (WL)
Number of subjects: 101
Study: 39186315

Group type: EXPERIMENTAL
Intervention: Rituximab therapy
Number of subjects: 14

Group type: COMPARATOR
Intervention: Any other therapy
Number of subjects: 14
Study: 39186326

Group type: EXPERIMENTAL
Intervention: Bone-anchored hearing implant surgery using the MONO procedure
Number of subjects: 51
Study: 39186356

Group type: EXPERIMENTAL
Intervention: Abdominal corset
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard method
Number of subjects: 100
Study: 39186380

Group type: EXPERIMENTAL
Intervention: Adipose-Derived Mesenchymal Stem Cell (ADR-001) Therapy
Number of subjects: 0
Study: 39186385

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 39186458

Group type: EXPERIMENTAL
Intervention: High-Intensity Blood Flow Restriction Training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 39186573

Group type: EXPERIMENTAL
Intervention: Cerebellar tDCS combined with semantic feature analysis (SFA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham tDCS combined with semantic feature analysis (SFA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cerebellar tDCS
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 60
Study: 39186588

Group type: EXPERIMENTAL
Intervention: Telemonitoring (MM e-coach)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard MM care
Number of subjects: 150
Study: 39186707

Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG) 10 mg/kg on days 1 and 8 of 21-day cycles
Number of subjects: 38
Study: 39186768

Group type: EXPERIMENTAL
Intervention: Sauti ya Vijana (SYV): The Voice of Youth intervention, consisting of a 10-session group-based intervention and two individual sessions.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sauti ya Vijana (SYV) intervention
Number of subjects: 100
Study: 39186770

Group type: EXPERIMENTAL
Intervention: Microgrants with peer mentoring
Number of subjects: 360

Group type: COMPARATOR
Intervention: Microgrants without peer mentoring
Number of subjects: 360

Group type: COMPARATOR
Intervention: Enhanced usual care (single microgrant plus monthly financial literacy education)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Extended microgrants (enhanced usual care plus monthly microgrants)
Number of subjects: 360
Study: 39186774

Group type: EXPERIMENTAL
Intervention: Integrated proactive supportive care pathways
Number of subjects: 12
Study: 39186785

Group type: EXPERIMENTAL
Intervention: Pelvic floor yoga program
Number of subjects: 240

Group type: COMPARATOR
Intervention: Physical conditioning program
Number of subjects: 240
Study: 39186921

Group type: EXPERIMENTAL
Intervention: Valbenazine 40 mg
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Valbenazine 80 mg
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Valbenazine
Number of subjects: 253

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Treatment-emergent adverse events (TEAEs)
Number of subjects: 253
Study: 39186971

Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA) psychotherapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Relapse Prevention (RP) psychotherapy
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Geospatial analyses
Number of subjects: 46
Study: 39187200

Group type: EXPERIMENTAL
Intervention: Cariprazine 3-12 mg/d for bipolar I mania
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cariprazine 1.5 mg/d or 3 mg/d for bipolar I depression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39187267

Group type: COMPARATOR
Intervention: 6-minute walk test (6MWT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-Time Sit-to-Stand (5STS) test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Grip strength
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trail Making Test (TMT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visuospatial Memory Test (VSMT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tap Fast
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TMT-A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TMT-B
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Digit Span Test (DST)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tap Fast score
Number of subjects: 0
Study: 39187401

Group type: EXPERIMENTAL
Intervention: Neratinib 240 mg once daily for up to 1 year
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study: 39187558

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) with pembrolizumab
Number of subjects: 837

Group type: EXPERIMENTAL
Intervention: Conventional radiotherapy (CRT) with pembrolizumab
Number of subjects: 837

Group type: COMPARATOR
Intervention: No radiotherapy (no RT) with pembrolizumab
Number of subjects: 837

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 837

Group type: EXPERIMENTAL
Intervention: Conventional radiotherapy (CRT)
Number of subjects: 837

Group type: COMPARATOR
Intervention: No radiotherapy (no RT)
Number of subjects: 837
Study: 39187595

Group type: EXPERIMENTAL
Intervention: anti-TIGIT antibody
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: anti-LAG3 antibody
Number of subjects: 12
Study: 39187749

Group type: EXPERIMENTAL
Intervention: Chronic migraine with medication overuse (CM-MO)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Episodic migraine (EM)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Migraine participants (both EM and CM-MO)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: miR-155
Number of subjects: 128

Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 128
Study: 39187802

Group type: EXPERIMENTAL
Intervention: Adjacent periodontal crevicular fluid (ToCF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Crevicular fluid from transepithelial abutment (TACF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transepithelial abutment (TA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Differentially abundant taxa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Differential network properties and association patterns
Number of subjects: 0
Study: 39187817

Group type: EXPERIMENTAL
Intervention: Online education (Zoom)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Onsite education (The Parker Institute, Denmark)
Number of subjects: 20
Study: 39187877

Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT)
Number of subjects: 72
Study: 39188412

Group type: EXPERIMENTAL
Intervention: Balance chiropractic therapy (BCT) for 20 days
Number of subjects: 240

Group type: COMPARATOR
Intervention: Traction therapy (TT)
Number of subjects: 240
Study: 39188413

Group type: EXPERIMENTAL
Intervention: Universal school-based prevention programs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39188767

Group type: EXPERIMENTAL
Intervention: Tacrolimus-rituximab (TAC-RTX)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Corticosteroids-cyclophosphamide (GC-CYC)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Plasma and urinary cytokines
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Cytokine clusters
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Plasma and urinary growth differentiation factor 15 (GDF15)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Plasma tumour necrosis factor α and urinary TNF-like weak inducer of apoptosis
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Baseline urinary CXCL13 concentration
Number of subjects: 34
Study: 39188940

Group type: EXPERIMENTAL
Intervention: Transdiagnostic group treatment protocol administered in a blended format
Number of subjects: 0

Group type: COMPARATOR
Intervention: Face-to-face treatment
Number of subjects: 0
Study: 39188943

Group type: EXPERIMENTAL
Intervention: FCN-437c 300 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: FCN-437c 400 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 39188996

Group type: EXPERIMENTAL
Intervention: Positron emission tomography/computed tomography after intravenous administration of 296 MBq
Number of subjects: 366

Group type: COMPARATOR
Intervention: Positron emission tomography/computed tomography
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: SoT-verification predominantly with conventional imaging
Number of subjects: 366
Study: 39189160

Group type: EXPERIMENTAL
Intervention: Telemonitoring (G_TECCU)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard care (G_Control)
Number of subjects: 150
Study: 39189473

Group type: EXPERIMENTAL
Intervention: Paroxysmal Atrial Fibrillation (PAF)
Number of subjects: 1369

Group type: COMPARATOR
Intervention: Persistent Atrial Fibrillation (Persistent AF)
Number of subjects: 1369
Study: 39189517

Group type: EXPERIMENTAL
Intervention: Amivantamab
Number of subjects: 0
Study: 39189547

Group type: EXPERIMENTAL
Intervention: Parathyroidectomy (PTX)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Observation without intervention (OBS)
Number of subjects: 150
Study: 39189858

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1200 mg orally twice daily for days 1 to 112
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard therapy without NAC
Number of subjects: 140
Study: 39190027

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 26
Study: 39190441

Group type: EXPERIMENTAL
Intervention: Mindfulness Coach (MC) mobile app
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 39190445

Group type: EXPERIMENTAL
Intervention: Therapeutic attachment controlled for avoidant attachment characteristics
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Growing engagement in therapy
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Therapeutic attachment controlled for anxious attachment characteristics
Number of subjects: 330
Study: 39190534

Group type: EXPERIMENTAL
Intervention: Nivolumab (anti-PD-1) plus ipilimumab (anti-CTLA4) for CD8-low patients (CD8 <15%)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Nivolumab monotherapy for CD8-high patients (CD8 ≥15%)
Number of subjects: 79
Study: 39190595

Group type: EXPERIMENTAL
Intervention: Transfemoral TAVI
Number of subjects: 24305
Study: 39190675

Group type: EXPERIMENTAL
Intervention: Web-based parent training program (Attend Behavior) for 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline survey
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-intervention survey
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1:1 interview with study team member
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Study retention and participant app usage data
Number of subjects: 0
Study: 39190813

Group type: EXPERIMENTAL
Intervention: CAD4TBv7
Number of subjects: 1392

Group type: EXPERIMENTAL
Intervention: C-reactive protein assay (CRP)
Number of subjects: 1392
Study: 39190826

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Number of subjects: 158
Study: 39190853

Group type: EXPERIMENTAL
Intervention: Complete mesocolic excision (CME)
Number of subjects: 1072

Group type: COMPARATOR
Intervention: D2 dissection
Number of subjects: 1072
Study: 39191095

Group type: EXPERIMENTAL
Intervention: Three-week multidisciplinary inpatient rehabilitation
Number of subjects: 0
Study: 39191132

Group type: EXPERIMENTAL
Intervention: Non-skin sparing mastectomy (non-SSM)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Skin sparing mastectomy (SSM)
Number of subjects: 153
Study: 39191270

Group type: EXPERIMENTAL
Intervention: Clinical Treatment Score post-5 years (CTS5)
Number of subjects: 1862

Group type: COMPARATOR
Intervention: Trastuzumab
Number of subjects: 1862

Group type: EXPERIMENTAL
Intervention: N3 status
Number of subjects: 1862

Group type: EXPERIMENTAL
Intervention: Tumor grade
Number of subjects: 1862

Group type: EXPERIMENTAL
Intervention: CTS5 risk categories
Number of subjects: 1862
Study: 39191373

Group type: EXPERIMENTAL
Intervention: Transitional tele-rehabilitation programme
Number of subjects: 60
Study: 39191568

Group type: EXPERIMENTAL
Intervention: MRgFUS thalamotomy
Number of subjects: 54
Study: 39191745

Group type: EXPERIMENTAL
Intervention: BNT162b2 booster (BB-B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CoronaVac booster (CC-C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CoronaVac (CC-C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BNT162b2 (CC-B)
Number of subjects: 0
Study: 39191755

Group type: EXPERIMENTAL
Intervention: Vactosertib (200 mg twice daily) in combination with pomalidomide
Number of subjects: 0
Study: 39191779

Group type: EXPERIMENTAL
Intervention: Cryoablation of an enlarging metastasis with continued ICI for a minimum of two additional cycles
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 17
Study: 39191809

Group type: EXPERIMENTAL
Intervention: Inhaled enriched heparin
Number of subjects: 27

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 27
Study: 39191926

Group type: EXPERIMENTAL
Intervention: Get Social condition (remotely delivered lifestyle intervention)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Traditional condition (in-person delivered lifestyle intervention)
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Get Social condition
Number of subjects: 329

Group type: COMPARATOR
Intervention: Traditional condition
Number of subjects: 329
Study: 39192022

Group type: EXPERIMENTAL
Intervention: High-intensity resistance training
Number of subjects: 32

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 32
Study: 39192036

Group type: EXPERIMENTAL
Intervention: Third-generation CAR T cells (HD-CAR-1) targeting CD19
Number of subjects: 9
Study: 39192162

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 400 mg two times daily for 24 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Mesalamine 1 g t.i.d. for 24 weeks (Control)
Number of subjects: 52
Study: 39192209

Group type: EXPERIMENTAL
Intervention: Intervention package (point-of-care tests including COVID-19 antigen tests, a diagnostic algorithm, and training and communication packages)
Number of subjects: 1098

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1098

Group type: EXPERIMENTAL
Intervention: Intervention package
Number of subjects: 1098
Study: 39192287

Group type: EXPERIMENTAL
Intervention: Predetected MDR Gram-negative bacteria
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: V-V ECMO-acquired MDR Gram-negative bacteria
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Annual hospital V-V ECMO volume
Number of subjects: 279

Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 279
Study: 39192291

Group type: EXPERIMENTAL
Intervention: SIRS diagnosed within the first 24 hours
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Class II bleeding
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Long-term vasopressor use
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Risk of acute coagulopathy
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Risk of pneumonia
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: ICU length of stay
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Mortality rate
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Random forest classifier predictive ability
Number of subjects: 439
Study: 39192309

Group type: EXPERIMENTAL
Intervention: Self-directed learning (SDL) model training based on Knowles' SDL principles
Number of subjects: 72

Group type: COMPARATOR
Intervention: Traditional learning model (TLM)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Self-directed learning (SDL) model
Number of subjects: 72
Study: 39192331

Group type: EXPERIMENTAL
Intervention: Sepsis Transition and Recovery (STAR) program
Number of subjects: 16
Study: 39192339

Group type: EXPERIMENTAL
Intervention: Topical antimicrobial plus RB-PDT
Number of subjects: 2

Group type: COMPARATOR
Intervention: Topical antimicrobial plus sham RB-PDT
Number of subjects: 2
Study: 39192345

Group type: EXPERIMENTAL
Intervention: Keep It Up! (KIU!), an evidence-based eHealth HIV prevention program
Number of subjects: 85
Study: 39192350

Group type: EXPERIMENTAL
Intervention: tofacitinib 5 or 10 mg twice daily (BID)
Number of subjects: 8404

Group type: EXPERIMENTAL
Intervention: tofacitinib 11 mg once daily (considered as tofacitinib 5 mg BID)
Number of subjects: 8404

Group type: EXPERIMENTAL
Intervention: Phase 3 and 3b/4 studies data
Number of subjects: 8404

Group type: EXPERIMENTAL
Intervention: ORAL Surveillance data
Number of subjects: 8404
Study: 39192597

Group type: EXPERIMENTAL
Intervention: Moderately hypofractionated preoperative radiotherapy (RT) 15 × 2.85 Gy
Number of subjects: 120
Study: 39193038

Group type: EXPERIMENTAL
Intervention: TARA intervention (12-week mindfulness-based training)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Waitlist-control group
Number of subjects: 100
Study: 39193146

Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS) in the mesencephalic locomotor region (MLR)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Sham stimulation (Control)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS)
Number of subjects: 62
Study: 39193150

Group type: EXPERIMENTAL
Intervention: Satralizumab
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 39193190

Group type: EXPERIMENTAL
Intervention: Venetoclax plus rituximab (VenR) for 2 years, with VenR for the first 6 months.
Number of subjects: 389

Group type: COMPARATOR
Intervention: Bendamustine plus rituximab (BR) for 6 months.
Number of subjects: 389
Study: 39193194

Group type: EXPERIMENTAL
Intervention: Step-tracking apps (Strava, Pacer, MapMyWalk, and PokémonGo) used at least three times per week for 10 weeks
Number of subjects: 462

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 462
Study: 39193207

Group type: EXPERIMENTAL
Intervention: As-needed albuterol-budesonide 180/160 µg pressurized metered-dose inhaler (pMDI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0